KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Debt (2016 - 2025)

NovoCure's Total Debt history spans 11 years, with the latest figure at $195.0 million for Q4 2025.

  • For Q4 2025, Total Debt rose 100.46% year-over-year to $195.0 million; the TTM value through Dec 2025 reached $195.0 million, up 100.46%, while the annual FY2025 figure was $195.0 million, 100.46% up from the prior year.
  • Total Debt for Q4 2025 was $195.0 million at NovoCure, roughly flat from $194.6 million in the prior quarter.
  • Across five years, Total Debt topped out at $569.7 million in Q1 2024 and bottomed at $97.0 million in Q2 2024.
  • The 5-year median for Total Debt is $561.4 million (2021), against an average of $402.5 million.
  • The largest annual shift saw Total Debt soared 274.94% in 2021 before it tumbled 82.9% in 2024.
  • A 5-year view of Total Debt shows it stood at $562.2 million in 2021, then grew by 0.59% to $565.5 million in 2022, then increased by 0.44% to $568.0 million in 2023, then crashed by 82.87% to $97.3 million in 2024, then surged by 100.46% to $195.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Total Debt are $195.0 million (Q4 2025), $194.6 million (Q3 2025), and $97.6 million (Q2 2025).